U.S. markets closed
  • S&P Futures

    3,628.25
    -8.25 (-0.23%)
     
  • Dow Futures

    29,762.00
    -112.00 (-0.37%)
     
  • Nasdaq Futures

    12,264.00
    +6.50 (+0.05%)
     
  • Russell 2000 Futures

    1,845.00
    -8.00 (-0.43%)
     
  • Crude Oil

    45.03
    -0.50 (-1.10%)
     
  • Gold

    1,785.60
    -2.50 (-0.14%)
     
  • Silver

    22.57
    -0.07 (-0.30%)
     
  • EUR/USD

    1.1973
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3331
    +0.0017 (+0.12%)
     
  • USD/JPY

    103.8750
    -0.2100 (-0.20%)
     
  • BTC-USD

    18,392.00
    +40.55 (+0.22%)
     
  • CMC Crypto 200

    363.69
    -6.82 (-1.84%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,597.04
    -47.67 (-0.18%)
     

Autolus Therapeutics to Participate in Upcoming Investor Conferences in June

LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in the following investor conferences in June:

  • Dr. Christian Itin, chairman and chief executive officer, will present at the Jefferies 2019 Healthcare Conference in New York on Wednesday, June 5 at 2:30 p.m. ET and will host one-on-one meetings with attendees. A live webcast of the presentation will be available on the investor relations section of Autolus’ website at https://www.autolus.com. An archived replay will be available on the company’s website for a period of 90 days after the conference.

  • Andrew Oakley, chief financial officer, and Christopher Vann, chief operating officer, will participate in the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes, Calif., hosting one-on-one meetings on Tuesday, June 11, 2019.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com.

Investor contact:
Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com

Media contacts:
Silvia Taylor
Vice President, Corporate Affairs and Communications
Autolus
+1-240-801-3850
s.taylor@autolus.com

Julia Wilson
JW Communications
+44 (0) 7818 430877
j.wilson@autolus.com